# OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation

Study · id `cardio:ct-nct05418556` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05418556](<https://clinicaltrials.gov/study/NCT05418556>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05418556

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3944 participants.

## Technical summary

Registry record NCT05418556. Randomized; no masking; primary purpose treatment. Start 2022-10-21 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3944 participants (planned count; ClinicalTrials.gov record NCT05418556, source copy `cardio:ctgov-nct05418556-2026-09-17`, retrieved 2026-10-26)
- Started: 2022-10-21 (actual) (ClinicalTrials.gov record NCT05418556, source copy `cardio:ctgov-nct05418556-2026-09-17`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT05418556, source copy `cardio:ctgov-nct05418556-2026-09-17`, retrieved 2026-10-26)
- Completion: 2032-12-31 (anticipated) (ClinicalTrials.gov record NCT05418556, source copy `cardio:ctgov-nct05418556-2026-09-17`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05418556, source copy `cardio:ctgov-nct05418556-2026-09-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05418556-2026-09-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
- Acronym: OPTIMIZE-APT
- Condition: Coronary Artery Disease
- Intervention (Drug): aspirin
- Lead sponsor: Asan Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Asan Medical Center (`cardio:org-asan-medical-center`)

## Provenance

Content hash: 21278e62280ca211212633d4a292428631ba11fe31d773499114e1f8def825ed
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
